In a regulatory filing, Roivant Sciences disclosed that its director Keith Manchester sold 6.9M shares of common stock on September 28th in a total transaction size of $79.7M.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on ROIV:
- Cantor biotech/biopharma analysts to hold an analyst/industry conference call
- Roivant Sciences files $1.5B mixed securities shelf
- Roivant Sciences price target raised to $16 from $14 at Goldman Sachs
- Immunovant announces $300M offering of common stock
- Unusually active option classes on open September 26th